Alexion Appoints Ludwig Hantson, Ph.D., as Chief Executive Officer

Alexion Appoints Ludwig Hantson, Ph.D., as Chief Executive Officer


Alexion Pharmaceuticals, Inc. today announced that its Board of Directors has appointed Ludwig N. Hantson, Ph.D., as Chief Executive Officer and member of the Board of Directors, effective immediately. Dr. Hantson most recently served as President and CEO of Baxalta, a successful spin-off as a public company from Baxter, and a global leader in the development of therapies for orphan and underserved diseases in hematology, immunology and oncology.



from Biotech News